Literature DB >> 3871342

Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties.

R W Colman, Y T Wachtfogel, U Kucich, G Weinbaum, S Hahn, R A Pixley, C F Scott, A de Agostini, D Burger, M Schapira.   

Abstract

Human plasma kallikrein consists of an N-terminal heavy chain of molecular weight (mol wt) 52,000, linked by disulfide bonds to two light chain variants (mol wt 36,000 or 33,000). Although the active catalytic site of kallikrein resides on the C-terminal light chain, the role of the N-terminal heavy chain is less clear. We therefore studied an enzyme designated beta-kallikrein, containing a single cleavage in the heavy chain (mol wt 28,000 + 18,000) and compared it to the enzyme, alpha-kallikrein, with an intact heavy chain. The rates of inactivation by C1 inhibitor of plasma alpha- and beta-kallikreins were kinetically identical, as measured by residual amidolytic activity, after various times of incubation with the inhibitor. Both enzymes reacted completely with C1 inhibitor after 18 hours and formed identical C1 inhibitor-kallikrein complexes of mol wt 195,000. The rate of activation of factor XII by alpha-kallikrein and beta-kallikrein was similar. In contrast, the rate of cleavage of high molecular weight kininogen (HMWK) by alpha-kallikrein was at least fivefold faster and the ratio of coagulant activity to amidolytic activity was fourfold greater than for beta-kallikrein. Plasma alpha-kallikrein, at concentrations potentially achievable in plasma, induced aggregation of neutrophils, but beta-kallikrein failed to elicit this response. In addition, human neutrophils pretreated with cytochalasin B released 2.46 +/- 0.10 microgram/10(7) cells of elastase antigen, but beta-kallikrein released only 0.25 +/- 0.10 micrograms/10(7) cells. These observations suggest that cleavage of the heavy chain influences the rate of cleavage of HMWK and decreases its coagulant activity. Moreover, an intact heavy chain appears to be requisite to support the ability of kallikrein to aggregate neutrophils and release elastase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871342

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

Review 2.  Molecular biology of tissue kallikrein.

Authors:  R J MacDonald; H S Margolius; E G Erdös
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

3.  Human neutrophils contain and bind high molecular weight kininogen.

Authors:  E J Gustafson; A H Schmaier; Y T Wachtfogel; N Kaufman; U Kucich; R W Colman
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Authors:  J Wang; A Matafonov; H Madkhali; F Mahdi; D Watson; A H Schmaier; D Gailani; Z Shariat-Madar
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

5.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

6.  Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

Authors:  A de Agostini; M Schapira; Y T Wachtfogel; R W Colman; S Carrel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 7.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.

Authors:  M Schapira; M A Ramus; B Waeber; H R Brunner; S Jallat; D Carvallo; C Roitsch; M Courtney
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

9.  Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.

Authors:  J J Abbink; A M Kamp; J H Nuijens; A J Erenberg; A J Swaak; C E Hack
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

Review 10.  Human tissue kallikrein in the treatment of acute ischemic stroke.

Authors:  Michelle Alexander-Curtis; Rick Pauls; Julie Chao; John J Volpi; Philip M Bath; Todd A Verdoorn
Journal:  Ther Adv Neurol Disord       Date:  2019-01-20       Impact factor: 6.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.